Bioxcel Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of BioXcel Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7.05% of BioXcel Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
SCHEDULE: QIA discloses 0.58% stake in BioXcel
Qatar Investment Authority filed a Schedule 13G/A reporting beneficial ownership of 156,066 BioXcel Therapeutics shares (0.58%) held via Q Boost Holding LLC, including warrant shares.
NASDAQ
Millennium Management and affiliated entities have reported an 8.4% beneficial ownership stake in BioXcel Therapeutics, Inc. as of December 31, 2025.
NASDAQ
Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a passive beneficial ownership of 5.2% in BioXcel Therapeutics, Inc.
NASDAQ
SCHEDULE 13G/A: Oaktree Entities Update Passive Stake in BioXcel Therapeutics, Holding 2.73% Through Warrants
Oaktree Fund Advisors, Oaktree Capital Management, and affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 2.73% in BioXcel Therapeutics, Inc. through warrants.
NASDAQ
Armistice Capital, LLC and its managing member Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. as of March 31, 2025.
NASDAQ
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a significant beneficial ownership stake of 9.99% in BioXcel Therapeutics, Inc. as of December 31, 2024.